Background {#Sec1}
==========

Malaria is a major global public health concern particularly in sub-Saharan Africa, with 219 million cases of malaria and approximately 435,000 deaths in 2017 \[[@CR1]\]. Most of the severe clinical cases and deaths were caused by *Plasmodium falciparum*. Furthermore, pregnant women and children under 5 years old are the main victims of falciparum malaria. To alleviate the global malaria burden in a susceptible population, sulfadoxine--pyrimethamine (SP) is recommended by the World Health Organization (WHO) for use as intermittent preventive treatment in pregnant women (IPTp) and infants (IPTi) in malaria-endemic regions \[[@CR2]\].

Equatorial Guinea (EG) is a hyperendemic area of year-round malaria transmission \[[@CR3]\], and the population is more frequently exposed to episodes of malaria \[[@CR4]\]. Recent studies demonstrated *P. falciparum* parasites are the predominant species in EG, leading to approximately 291,700 cases in 2016; 15% of the deaths from this species were in children under 5 years old \[[@CR5]\]. The authorities have deployed a series of measures that include effective anti-malarial drugs, vector control and case management for malaria control \[[@CR6]\]. In 2004, The Bioko Island Malaria Control Project (BIMCP) was initiated on Bioko Island \[[@CR7]\]. That project succeeded in reducing the infection rate, anaemia and child mortality \[[@CR6]\]. Subsequently, similar measures have been adopted and were applied on mainland EG by the Equatorial Guinea Malaria Control Initiative (EGMCI) in 2007 \[[@CR8]\]. In EG, SP has been used as a second-line treatment in cases of uncomplicated falciparum malaria for several decades. Furthermore, it was administered as the partner drug with artesunate as a first-line drug because of chloroquine treatment failure and as a malaria prophylaxis since 2004 \[[@CR9]\], which may have led to *P. falciparum* isolates undergoing sustainable selection pressure. Soon afterwards, SP was replaced by artemisinin-based combination therapy (ACT) in response to widespread drug resistance in 2009, but it still remains the only choice for IPTp \[[@CR10]\]. Of even greater concern, SP resistance (SPR) had already evolved in most African countries before SP was implemented as the recommended treatment. To ensure the prophylactic efficacy of this approach and support the national anti-malarial policy, large-scale screening and surveillance of SP drug resistance is highly recommended \[[@CR11]\].

Targeting the *P. falciparum* enzymes dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), SP acts as a synergistic inhibitor of folate in the parasite \[[@CR12], [@CR13]\]. In vitro and in vivo studies have demonstrated that SPR is mainly conferred by amino acid point mutations at codons N51I, C59R, S108N, and I164L of *Pfdhfr* and S436A, A437G, K540E, A581G, and A613S of *Pfdhps* \[[@CR14]\]. These hotspot mutations are suggested to be gradually displayed with the increase of SPR \[[@CR15]\]. Many clinical failures have been reported after SP treatment was found in Africa \[[@CR16]--[@CR18]\]. Thus, an urgent need exists to continue monitoring and assessing resistance in *P. falciparum* populations when determining whether to administer this drug for prevention.

On Bioko Island, IPTp was introduced in 2004 \[[@CR7], [@CR9]\], and the Ministry of Health has implemented the use of two doses of SP during pregnancy and antenatal care, starting from the second trimester and 1 month apart \[[@CR19]\]. An assessment of the prevalence of mutations in *P. falciparum* genes related to SPR on Bioko Island is needed to provide complementary information for this preventive strategy. In the current study, an assessment of the prevalence of the *Pfdhfr* and *Pfdhps* gene mutations and haplotypes was conducted on *P. falciparum* isolates collected from Bioko Island, EG.

Methods {#Sec2}
=======

Study area and samples collection {#Sec3}
---------------------------------

The study was performed in 2013--2014 on Bioko Island, the Insular Region of EG, where malaria is endemic and has continuous transmission throughout the year. Venous blood (3 ml) was collected from *P. falciparum*-infected patients and confirmed by thick and thin smears stained with diluted Giemsa. Additionally, positive blood spots were air dried, individually reserved in coded plastic bags with silica desiccant beads, and kept at room temperature for further molecular assessment.

Ethics statement {#Sec4}
----------------

The Ethics Committees of Malabo Regional Hospital on Bioko Island gave scientific and ethical permission (EGCNGD-071). Consent was obtained from all persons or their legal guardians before sample collection.

DNA extraction and PCR {#Sec5}
----------------------

Genomic DNA was extracted from dried filtered bloodspots (DBS) by following the Chelex-100 extraction procedure described in the previous report \[[@CR20]\]. The *Pfdhfr* and *Pfdhps* genes were amplified by nested PCR, and the conditions for amplification were as previously described \[[@CR21]\]. The mutations of the *Pfdhfr* and *Pfdhps* genes in the amplified nested PCR products were purified and detected subsequently by Sanger sequencing (Genewiz, Soochow, China). All sequences were analysed using DNAstar (DNASTAR Inc., Madison, WI, USA).

Data analysis {#Sec6}
-------------

All data were analysed with SPSS 18 (SPSS Inc., Chicago, IL, USA). The percentages of single nucleotide polymorphisms (SNPs) and haplotypes were calculated with a 95% CI as described previously \[[@CR22]\]. Differences in allele prevalence were compared using Pearson Chi square test or Fisher's exact test, when conditions were appropriate. To determine the association between the SNPs of the *Pfdhfr* and *Pfdhps* genes, linkage disequilibrium (LD) tests were performed for each possible pair-wise SNP implicated as a drug-resistant marker in the two genes by calculating the D' and *r*^2^ values using Haploview 4.2 software \[[@CR23]\]. P values, less than 0.05 indicated significance.

Results {#Sec7}
=======

General information {#Sec8}
-------------------

In total, 180 isolates were evaluated. Then, 167 and 158 samples were successfully amplified, sequenced and genotyped for the *Pfdhfr* and *Pfdhps* genes, respectively. Of these successfully sequenced isolates, 130 sequences without any mixed types in *Pfdhfr* and *Pfdhps* were analysed for combined genotypes.

Prevalence of individual point mutations in *Pfdhfr* and *Pfdhps* {#Sec9}
-----------------------------------------------------------------

A high prevalence of *Pfdhfr* mutant alleles was detected in the analysed samples. The two major mutations, N51I (97.60%; 163/167) and S108N (97.01%; 162/167), showed similar prevalence, followed by C59R (87.43%; 146/167). The C59R mutant allele showed lower prevalence compared to N51I and S108N (χ^2^ = 6.141, P = 0.013; χ^2^ = 6.082, P = 0.014). No mutation was identified at positions 50 and 164. The key mutation of *Pfdhps* linked to sulfadoxine resistance at codon A437G was predominant at 90.51% (143/158), while the prevalence of the S436A mutation was found to be 20.25% (32/158), and the K540E, A581G and A613S mutations were less frequent, occurring at rates of 5.06% (8/158), 0.63% (1/158) and 3.16% (5/158), respectively. The A437G mutation occurred at a significantly different rate compared with S436A (χ^2^ = 153.837, P \< 0.001), K540E (χ^2^ = 234.34, P \< 0.001), A581G (χ^2^ = 259.538, P \< 0.001), and A613S (χ^2^ = 249.161, P \< 0.001). Similar to A437G, the S436A occurred at a significantly different rate compared with K540E (χ^2^ = 17.929, P \< 0.001), A581G (χ^2^ = 34.142, P \< 0.001) and A613S (χ^2^ = 24.726, P \< 0.001) (Table [1](#Tab1){ref-type="table"}).Table 1Prevalence of *Pfdhfr* and *Pfdhps* SNPs in *Plasmodium falciparum* isolates from Bioko Island, Equatorial GuineaGeneSNPWild typeMutationMixed typen (%, 95% CI)n (%, 95% CI)n (%, 95% CI)Pfdhfr (n = 167)513 (1.80, − 0.22 to 3.82)163 (97.60, 95.28 to 99.92)1 (0.60, − 0.57 to 1.77)5912 (7.19, 3.27 to 11.11)146 (87.43, 82.4 to 92.46)9 (5.39, 1.97 to 8.81)1083 (1.80, − 0.22 to 3.82)162 (97.01, 94.43 to 99.59)2 (1.20, − 0.45 to 2.85)Pfdhps (n = 158)436115 (72.78, 65.84 to 79.72)32 (20.25, 13.98 to 26.52)11 (6.96, 2.99 to 10.93)43712 (7.59, 3.46 to 11.72)143 (90.51, 85.94 to 95.08)3 (1.90, − 0.23 to 4.03)540146 (92.41, 88.28 to 96.54)8 (5.06, 1.64 to 8.48)4 (2.53, 0.08 to 4.98)581152 (96.20, 93.22 to 99.18)1 (0.63, − 0.6 to 1.86)5 (3.16, 0.43 to 5.89)613153 (96.84, 94.11 to 99.57)5 (3.16, 0.43 to 5.89)0 (0.00)*SNPs* single nucleotide polymorphisms, *n* number, *CI* confidence interval

Prevalence of *Pfdhfr* and *Pfdhps* haplotypes {#Sec10}
----------------------------------------------

In the reconstitution of the haplotypes, 3 and 8 distinct genotypes were observed in *Pfdhfr* and *Pfdhps*, respectively, and mixed genotypes were also found in both genes. For *Pfdhfr*, only 1.2% (2/167) of the isolates were wild type CNCSI whereas 86.83% (145/167) carried the triple mutation C[IRN]{.ul}I. The double mutant C[I]{.ul}C[N]{.ul}I occurred with low prevalence at 5.99% (10/167). The overall prevalence of the mixed haplotypes was 5.99% (10/167) as follows: 0.6% (1/167) CNC/[R]{.ul}SI, 4.19% (7/167) C[I]{.ul}C/[RN]{.ul}I, 0.6% (1/167) C[IR]{.ul}S/[N]{.ul}I, and 0.6% (1/167) CN/[I]{.ul}C/[R]{.ul}S/[N]{.ul}I. For *Pfdhps*, the single mutated haplotype S[G]{.ul}KAA was present in 62.66% (99/158) of the samples, followed by the double mutant haplotypes [AG]{.ul}KAA in 10.76% (17/158), whereas only one isolate exhibited the triple mutated haplotype S[GEG]{.ul}A. Of the remaining samples, 5.7% (9/158) harboured [A]{.ul}AKAA, 4.43% (7/158) S[GE]{.ul}AA, 0.63% (1/158) S[G]{.ul}KA[S]{.ul}, and 2.53% (4/158) [AG]{.ul}KA[S]{.ul}. The overall prevalence of mixed haplotypes was 11.39% (18/158) as follows: 0.63% (1/158) S/[A]{.ul}AKAA, 3.8% (6/158) S/[AG]{.ul}KAA, 1.9% (3/158) S[G]{.ul}K/[E]{.ul}AA, 0.63% (1/158) S[G]{.ul}KA/[G]{.ul}A, 1.27% (2/158) [AG]{.ul}KA/[G]{.ul}A, 0.63% (1/158) S/[AG]{.ul}KA/[G]{.ul}A, 1.9% (3/158) S/[A]{.ul}A/[G]{.ul}KAA, and 0.63% (1/158) S[G]{.ul}K/[E]{.ul}A/[G]{.ul}A (Table [2](#Tab2){ref-type="table"}).Table 2Prevalence of *Pfdhfr* and *Pfdhps* haplotypes in *Plasmodium falciparum* isolates from Bioko Island, Equatorial GuineaGeneCategoryHaplotypen (%, 95% CI)Pfdhfr (n = 167)Wild typeCNCSI2 (1.20, − 0.45 to 2.85)Double mutantC[I]{.ul}C[N]{.ul}I10 (5.99, 2.39 to 9.59)Triple mutantC[IRN]{.ul}I145 (86.83, 81.7 to 91.96)Mixed typeCNC/[R]{.ul}SI1 (0.60, − 0.57 to 1.77)C[I]{.ul}C/[RN]{.ul}I7 (4.19, 1.15 to 7.23)C[IR]{.ul}S/[N]{.ul}I1 (0.60, − 0.57 to 1.77)CN/[I]{.ul}C/[R]{.ul}S/[N]{.ul}I1 (0.60, − 0.57 to 1.77)Pfdhps (n = 158)Wild typeSAKAA2 (1.27, − 0.48 to 3.02)Single mutant[A]{.ul}AKAA9 (5.70, 2.08 to 9.32)S[G]{.ul}KAA99 (62.66, 55.12 to 70.2)Double mutant[AG]{.ul}KAA17 (10.76, 5.93 to 15.59)S[GE]{.ul}AA7 (4.43, 1.22 to 7.64)S[G]{.ul}KA[S]{.ul}1 (0.63, − 0.6 to 1.86)Triple mutant[AG]{.ul}KA[S]{.ul}4 (2.53, 0.08 to 4.98)S[GEG]{.ul}A1 (0.63, − 0.6 to 1.86)Mixed typeS/[A]{.ul}AKAA1 (0.63, − 0.6 to 1.86)S/[AG]{.ul}KAA6 (3.80, 0.82 to 6.78)S[G]{.ul}K/[E]{.ul}AA3 (1.90, − 0.23 to 4.03)S[G]{.ul}KA/[G]{.ul}A1 (0.63, − 0.6 to 1.86)[AG]{.ul}KA/[G]{.ul}A2 (1.27, − 0.48 to 3.02)S/[A]{.ul}A/[G]{.ul}KAA3 (1.90, − 0.23 to 4.03)S/[AG]{.ul}KA/[G]{.ul}A1 (0.63, − 0.6 to 1.86)S[G]{.ul}K/[E]{.ul}A/[G]{.ul}A1 (0.63, − 0.6 to 1.86)*n* number, mutated alleles are underlined, *CI* confidence interval

*Pfdhfr* and *Pfdhps* allele combinations {#Sec11}
-----------------------------------------

When the *Pfdhfr* and *Pfdhps* haplotypes were combined, 12 genotypes were verified and are shown in Table [3](#Tab3){ref-type="table"}. Quadruple mutant haplotypes with a triple *Pfdhfr* and a single *Pfdhps* mutation (C[IRN]{.ul}I-S[G]{.ul}KAA) was the most common at 65.38% (85/130). One sample at the *Pfdhfr* and *Pfdhps* loci was fully a wild type. The second prevalent haplotype was C[IRN]{.ul}I-[AG]{.ul}KAA with a frequency of 12.31% (16/130). The quintuple mutation (C[IRN]{.ul}I-S[GE]{.ul}AA) and sextuple mutation (C[IRN]{.ul}I-S[GEG]{.ul}A) were found in 4.62% (6/130) and 0.77% (1/130) of the isolates, respectively. The occurrence of other combined haplotypes was generally low: 0.77% (1/130) CNCSI-S[G]{.ul}KAA, 4.62% (6/130) C[I]{.ul}C[N]{.ul}I-S[G]{.ul}KAA, 0.77% (1/130) C[IRN]{.ul}I-SAKAA, 0.77% (1/130) C[I]{.ul}C[N]{.ul}I-S[GE]{.ul}AA, 5.38% (7/130) C[IRN]{.ul}I-[A]{.ul}AKAA, 0.77% (1/130) C[IRN]{.ul}I-S[G]{.ul}KAS, and 3.08% (4/130) C[IRN]{.ul}I-[AG]{.ul}KA[S]{.ul}.Table 3Prevalence of *Pfdhfr* and *Pfdhps* allele combinations in *Plasmodium falciparum* isolates from Bioko Island, Equatorial GuineaGeneCategoryHaplotypen (%, 95% CI)Pfdhfr/Pfdhps (n = 130)Wild typeCNCSI-SAKAA1 (0.77, − 0.73 to 2.27)Single mutantCNCSI-S[G]{.ul}KAA1 (0.77, − 0.73 to 2.27)Triple mutantC[I]{.ul}C[N]{.ul}I-S[G]{.ul}KAA6 (4.62, 1.01 to 8.23)C[IRN]{.ul}I-SAKAA1 (0.77, − 0.73 to 2.27)Quadruple mutantC[I]{.ul}C[N]{.ul}I-S[GE]{.ul}AA1 (0.77, − 0.73 to 2.27)C[IRN]{.ul}I-[A]{.ul}AKAA7 (5.38, 1.5 to 9.26)C[IRN]{.ul}I-S[G]{.ul}KAA85 (65.38, 57.2 to 73.56)C[IRN]{.ul}I-[AG]{.ul}KAA16 (12.31, 6.66 to 17.96)Quintuple mutantC[IRN]{.ul}I-S[GE]{.ul}AA6 (4.62, 1.01 to 8.23)C[IRN]{.ul}I-S[G]{.ul}KA[S]{.ul}1 (0.77, − 0.73 to 2.27)Sextuple mutantC[IRN]{.ul}I-[AG]{.ul}KA[S]{.ul}4 (3.08, 0.11 to 6.05)C[IRN]{.ul}I-S[GEG]{.ul}A1 (0.77, − 0.73 to 2.27)*n* number, *CI* confidence interval, mutated alleles are underlined

Linkage disequilibrium (LD) test for *Pfdhfr* and *Pfdhps* haplotypes {#Sec12}
---------------------------------------------------------------------

The LD pattern for each SNP in the *Pfdhfr* and *Pfdhps* genes was assessed (Fig. [1](#Fig1){ref-type="fig"}). For the *Pfdhfr* gene, base substitution mutations of T152A, T175C and G323A were related to the single amino acid mutations of N51I, C59R, S108N, respectively. Similarly, the T1482G, C1486G, A1794G, and G2013T in the *Pfdhps* gene indicated mutations of S436A, A437G, K540E, and A613S, respectively.Fig. 1Linkage disequilibrium (LD) between pairs of single nucleotide polymorphisms (SNPs) located in *Pfdhfr* and *Pfdhps* and implicated in drug resistance for *Plasmodium falciparum* isolates from Bioko Island, Equatorial Guinea. For the *Pfdhfr* gene, base substitution mutations of T152A, T175C, and G323A are related to single amino acid mutations of N51I, C59R, and S108N, respectively. Similarly, the T1482G, C1486G, A1794G, and G2013T in the *Pfdhps* gene are related to mutations of S436A, A437G, K540E, and A613S, respectively. According to the four-gamete test, these SNPs are divided into two blocks (black frame). The number in the square indicates a D' value. The square with dark red and light red indicates a linkage that was statistically significant (P \< 0.05). The square with Cambridge blue indicates a linkage is present but is not statistically significant (P \> 0.05). The square with white indicates no linkage is present

Several statistically significant associations were found among the SNPs located in both the *Pfdhfr* and *Pfdhps* genes (Fig. [1](#Fig1){ref-type="fig"}). For the *Pfdhfr* gene, T152A, T175C and G323 were in an LD block. The T152A (N51I) were significantly associated with the SNPs (T175C, C59R and G323A, S108N) with a D' value of 0.84 (P \< 0.05) and 1.0 (P \< 0.05), respectively. Similarly, the T175C was significantly associated with the G323A (0.71, P \< 0.05). For the *Pfdhps* gene, T1482G, C1486G, A1794G, and G2013T formed an LD block. The sole SNP (T1482G, S436A) were significantly associated with the SNPs (C1486G, A437G; A1794G, K540E; and G2013T, A613S) with D' values of 0.75, 1.0 and 0.73, respectively. The SNP (T152A) of the *Pfdhfr* gene coding N51I was significantly associated with the C1486G, and the value is 0.68. No such association was detected in the other SNPs of either the *Pfdhfr* or *Pfdhps* genes.

Discussion {#Sec13}
==========

The rapid and widespread development of anti-malarial drug resistance is directly influencing and hindering the process of malaria control, prevention and elimination \[[@CR24]\]. Surveillance with molecular markers has allowed the early detection of drug resistance susceptibility and may provide fundamental information for drug policy \[[@CR25]\]. The current study displays the mutations and haplotypes of the *Pfdhfr* and *Pfdhps* genes from isolates collected from the general population on Bioko Island, thus allowing the degree of SPR in this malaria hotspot to be inferred.

The results demonstrate that *Pfdhfr* polymorphism associated with SPR persists at high frequency. A high prevalence of the *Pfdhfr* N51I mutation in 97.60% and the S108N mutation in 97.01% of the samples was found among the *P. falciparum* population on Bioko Island (Table [1](#Tab1){ref-type="table"}), and these mutations also had been found at a very high level (97.9 and 99.1%, respectively) in the Democratic Republic of Congo (DRC) in 2008 \[[@CR26]\]. For C59R, the level was significantly lower than for N51I and S108N, similar to observations in the mainland of EG \[[@CR4]\]. Like neighbouring countries, *Pfdhfr* I164L, which is related to high-grade SPR, has been reported at low proportions (1.4%) in rural areas of the EG mainland \[[@CR4], [@CR27]\]. Fortunately, this mutation was not found in any isolates within the study. Although the mutations of *Pfdhfr* C50R and I164L are not found in the present data, the high prevalence of three well-characterized mutations in *Pfdhfr* (N51I, C59R, S108N) indicate the *P. falciparum* isolates from Bioko island display high pyrimethamine resistance that needs to be addressed by the EGMCI. For the *Pfdhfr* haplotypes, 86.83% of the isolates carried the *Pfdhfr* triple mutation (C[IRN]{.ul}I) (Table [2](#Tab2){ref-type="table"}) and was reported in 80% of *P. falciparum* infections in 2005 from the mainland of EG, 100% in 2005 in Cameroon \[[@CR28]\], and 72.4% in Gabon \[[@CR29]\]. This triple mutation is an important SPR indicator, but its detrimental effects may be largely compromised by an absence of the *Pfdhfr* I164L mutation \[[@CR30], [@CR31]\]. The frequency of the *Pfdhfr* double mutant C[I]{.ul}C[N]{.ul}I was 5.99% (Table [2](#Tab2){ref-type="table"}), and this genotype has a lesser degree of resistance compared with the triple mutation C[IRN]{.ul}I \[[@CR29]\]. For the dominant mutant haplotype C[IRN]{.ul}I (86.83%) and the double mutant haplotype C[I]{.ul}C[N]{.ul}I (5.99%), the results are consistent with previous studies in EG and Central Africa \[[@CR4], [@CR10], [@CR32], [@CR33]\]. If the C[IRN]{.ul}I haplotype is found concurrently with the *Pfdhps* mutations, it is associated with a high level of resistance \[[@CR34]\]. The reported prevalence of the *Pfdhfr* triple mutation was also lower than those previously reported at the site where the proportion of the *Pfdhfr* triple mutation reached a frequency of 97%. Only 1.2% of the isolates (2/167) were a pure *Pfdhfr* wild type (CNCSI) (Table [2](#Tab2){ref-type="table"}). The results indicate that almost all samples collected harbour pyrimethamine resistance.

Compared with the mutations of the *Pfdhfr* gene, the mutations of the *Pfdhps* gene exhibit a relatively low prevalence, except for the A437G mutation (90.51%, 143/158) (Table [1](#Tab1){ref-type="table"}), which is also common in other EG regions and several African countries \[[@CR27], [@CR31], [@CR35]\]. This mutation has been reported to occupy the key position of the initial mutation of sulfadoxine resistance, and its resistance increases along with the augmentation of other mutations in *Pfdhps* \[[@CR36]\]. Although the prevalence of S436A is significantly lower than that of A437G, it is higher than for other mutations, including K540E, A581G and A613S. In Central Africa, the *Pfdhps* K540E mutation was less prevalent, which was also confirmed in this study (5.06%, 8/158) (Table [1](#Tab1){ref-type="table"}). This mutation is more common in East Africa, particularly in Tanzania \[[@CR37]\] and Uganda \[[@CR17]\]. The WHO has recommended that IPT with SP should be abandoned in areas where the K540E mutation has been detected at \> 95% and *Pfdhps* the A581G mutations are detected at \> 10% because it could be ineffective \[[@CR11]\]. Fortunately, only 5.06% (5/158) of the isolates showed the *Pfdhps* K540E mutation, and 0.63% (1/158) of the isolates harboured the A581G mutation in current survey (Table [1](#Tab1){ref-type="table"}). The relatively low prevalence of these mutations suggests that IPT-SP can possibly be efficacious on Bioko Island, EG. The A613S mutations were detected in 3.16% (5/158) of the isolates, which is consistent with reports in Central African countries, including the DRC \[[@CR27]\] and Cameroon \[[@CR29]\]. For the *Pfdhps* haplotype, the single-mutant S[G]{.ul}KAA haplotype predominates in our results (62.66%) (Table [2](#Tab2){ref-type="table"}), similar to observations made in Gabon \[[@CR38]\] and the DRC \[[@CR39]\]. [AG]{.ul}KAA is present in 10.76% of the isolates (Table [2](#Tab2){ref-type="table"}), and an increased trend was detected in Gabon between 2013 and 2014 \[[@CR38]\]. Parasites with double- and triple-mutant *Pfdhps* haplotypes were observed at a low frequency (Table [2](#Tab2){ref-type="table"}), suggesting a low tendency in the emergence and development of the sulfadoxine resistance alleles.

The combination of the *Pfdhfr* and *Pfdhps* mutant alleles generated 12 different haplotypes in the present survey (Table [3](#Tab3){ref-type="table"}). Only one wild-type haplotype (CNCSI-SAKAA) was found in this study (Table [3](#Tab3){ref-type="table"}). The quadruple mutant (C[IRN]{.ul}I-S[G]{.ul}KAA) was predominant, with a prevalence of 65.38% (Table [3](#Tab3){ref-type="table"}), which is higher than reports from mainland EG (54%) \[[@CR4]\]. The saturation of the *Pfdhfr* triple mutants could further induce the *Pfdhps* mutants, and thus, the presence of quadruple mutants (C[IRN]{.ul}I-S[G]{.ul}KAA) was common \[[@CR40]\]. Although quintuple mutant genotypes (C[IRN]{.ul}I-S[GE]{.ul}AA) are highly linked to SP failure \[[@CR34]\], this mutant was detected at a rate of 4.62% (Table [3](#Tab3){ref-type="table"}). WHO recommends surveillancefor this genotype and inhibition of IPTp-SP when the prevalence of this quintuple mutant exceeds 50% \[[@CR31]\]. To date, this quintuple mutant is less than 10% in other areas of EG \[[@CR4], [@CR10]\]. Previous in vitro studies demonstrated that the quadruple mutant (C[IRNI]{.ul}-S[G]{.ul}KAA) has a less deleterious effect on SP-IPT than the quintuple mutant genotypes (C[IRN]{.ul}I-S[GE]{.ul}AA) \[[@CR41]\]. Notably, the 'super resistant' alleles (C[IRN]{.ul}I-S[GEG]{.ul}A) may render SP ineffective \[[@CR42]\], but these were detected in only one isolate. Although this occurrence is low, sustainable monitoring for SPR and avoiding the growth of super resistance alleles are still critical.

Although the LD analysis of the SNPs between the *Pfdhfr* and *Pfdhps* genes showed a strong linkage between N51I and A437G, those main SNPs of the *Pfdhfr* and *Pfdhps* genes form two independent LD blocks, respectively. These results indicate that the mutations located in the *Pfdhfr* and *Pfdhps* genes have relative independence. However, combined chemotherapy will likely lead to the occurrence and progress of resistance gene mutations even though the *Pfdhfr* and *Pfdhps* genes are located on different chromosomes \[[@CR40]\]. For the *Pfdhfr* gene, T152A, T175C, and G323A develop as a block. When distributed in the *Pfdhfr* gene, these SNPs exhibit strong linkage, particularly of N51I and S108N (D': 0.71--1, P \< 0.05). For the *Pfdhps* gene, the T1482G, C1486G, A1794G, and G2013T were found in an LD block. Although the SNPs in *Pfdhps* gene show weak linkage and no significant differences (P \> 0.05), strong linkages were also commonly detected from S436A and other mutations, including A437G, K540E and A613S. Notably, the study had weaknesses, including the small sample size and the lack of full-length DNA sequences for the *Pfdhfr* and *Pfdhps* genes. In the present study, a 594-bp fragment of the *Pfdhfr* and a 711-bp fragment of the *Pfdhps* gene were amplified, based on previous study \[[@CR21]\]. The sequences from these two fragments provide only limited information for LD analysis. Thus, the complete nucleotide sequences from the *Pfdhfr* and *Pfdhps* genes and the microsatellite loci flanking these genes \[[@CR43]\] need to be amplified and genotyped in further study. Genetic diversity information and differentiation data from microsatellite loci flanking the *Pfdhfr* and *Pfdhps* genes will demonstrate whether the *P. falciparum* isolates have ever undergone selection in response to SP and may provide valuable information to solve anti-malarial drug resistance, particularly SPR.

Conclusions {#Sec14}
===========

The results of this study indicate that this area had a high prevalence of the *Pfdhfr* triple mutation (C[IRN]{.ul}I) and the *Pfdhps* single mutation (S[G]{.ul}KAA), which could undermine the efficacy of SP for chemoprevention strategy. To avoid increases in SPR, continuous molecular monitoring and additional control efforts are urgently needed.
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